More and more drugmakers are outsourcing their drug trials to contract research organizations, says Pharmalot's Ed Silverman. So it should come as no surprise that CROs are the latest sector to see some large acquisitions and interest from investors.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.